Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p127 | (1) | ICCBH2019

Burosumab therapy in pediatric patients with X-linked hypophosphatemia improves body composition

Brener Avivit , Cleper Roxana , Lebenthal Yael , Zeitlin Leonid

Objective: Burosumab, a recombinant human monoclonal antibody that inhibits FGF23, was approved by the FDA in April, 2018 for the treatment of X-linked hypophosphatemia (XLH) in children and adults. XLH pediatric patients are typically affected with lower extremity deformities, short stature, bone pain, and limited physical activity. Burosumab is superior to conventional therapy in normalizing blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing...